公开(公告)号：US20230241211A1

公开(公告)日：2023-08-03

申请号：US18160386

申请日：2023-01-27

Applicant: GENMAB A/S

Inventor： Christopher W. L. CHIU ,  Mariana Cota STIRNER ,  Minh H. DINH ,  Iliana Edith SZAFER-GLUSMAN

IPC: A61K39/395 ,  A61K31/454 ,  A61K31/519 ,  A61P35/00 ,  A61P7/00

CPC classification number: A61K39/3955 ,  A61K31/454 ,  A61K31/519 ,  A61P35/00 ,  A61P7/00 ,  A61K2039/545

Abstract: Provided are methods of clinical treatment of Diffuse Large B-cell Lymphoma (for example, relapsed and/or refractory Diffuse Large B-cell Lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with lenalidomide or ibrutinib and lenalidomide.

公开(公告)号：US20230303693A1

公开(公告)日：2023-09-28

申请号：US18160391

申请日：2023-01-27

Applicant: GENMAB A/S

Inventor： Christopher W. L. CHIU ,  Mariana Cota STIRNER ,  Minh H. DINH ,  IIiana Edith SZAFER-GLUSMAN

IPC: C07K16/28 ,  A61P35/00 ,  A61K47/68 ,  A61K39/395 ,  A61K31/675 ,  A61K31/704 ,  A61K31/573

CPC classification number: C07K16/2809 ,  A61P35/00 ,  A61K47/6811 ,  A61K47/6867 ,  A61K39/3955 ,  A61K31/675 ,  A61K31/704 ,  A61K31/573 ,  C07K16/2887 ,  A61K2039/507

Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone).